(Q33885729)

29 July 2017

1 reference

title

Taxol in the management of cancers of the breast and the ovary (English)

1 reference

29 July 2017

1 reference

Khayat D

1

1 reference

29 July 2017

Antoine EC

series ordinal

2

1 reference

29 July 2017

Coeffic D

series ordinal

3

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

18

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

242-260

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

29 July 2017

1 reference

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Cisplatin as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Cisplatin and its analogues in the treatment of advanced breast cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357900009031828

10.3109/07357900009031828

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference